Cargando…
Metabolic Fingerprinting of Fabry Disease: Diagnostic and Prognostic Aspects
Fabry disease (FD) is an X-linked lysosomal disease due to a deficiency in the activity of the lysosomal-galactosidase A (GalA), a key enzyme in the glycosphingolipid degradation pathway. FD is a complex disease with a poor genotype–phenotype correlation. In the early stages, FD could involve the pe...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415061/ https://www.ncbi.nlm.nih.gov/pubmed/36005574 http://dx.doi.org/10.3390/metabo12080703 |
_version_ | 1784776139368038400 |
---|---|
author | Rocchetti, Maria Teresa Spadaccino, Federica Catalano, Valeria Zaza, Gianluigi Stallone, Giovanni Fiocco, Daniela Netti, Giuseppe Stefano Ranieri, Elena |
author_facet | Rocchetti, Maria Teresa Spadaccino, Federica Catalano, Valeria Zaza, Gianluigi Stallone, Giovanni Fiocco, Daniela Netti, Giuseppe Stefano Ranieri, Elena |
author_sort | Rocchetti, Maria Teresa |
collection | PubMed |
description | Fabry disease (FD) is an X-linked lysosomal disease due to a deficiency in the activity of the lysosomal-galactosidase A (GalA), a key enzyme in the glycosphingolipid degradation pathway. FD is a complex disease with a poor genotype–phenotype correlation. In the early stages, FD could involve the peripheral nervous system (acroparesthesias and dysautonomia) and the ski (angiokeratoma), but later kidney, heart or central nervous system impairment may significantly decrease life expectancy. The advent of omics technologies offers the possibility of a global, integrated and systemic approach well-suited for the exploration of this complex disease. In this narrative review, we will focus on the main metabolomic studies, which have underscored the importance of detecting biomarkers for a diagnostic and prognostic purpose in FD. These investigations are potentially useful to explain the wide clinical, biochemical and molecular heterogeneity found in FD patients. Moreover, the quantitative mass spectrometry methods developed to evaluate concentrations of these biomarkers in urine and plasma will be described. Finally, the complex metabolic biomarker profile depicted in FD patients will be reported, which varies according to gender, types of mutations, and therapeutic treatment. |
format | Online Article Text |
id | pubmed-9415061 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94150612022-08-27 Metabolic Fingerprinting of Fabry Disease: Diagnostic and Prognostic Aspects Rocchetti, Maria Teresa Spadaccino, Federica Catalano, Valeria Zaza, Gianluigi Stallone, Giovanni Fiocco, Daniela Netti, Giuseppe Stefano Ranieri, Elena Metabolites Review Fabry disease (FD) is an X-linked lysosomal disease due to a deficiency in the activity of the lysosomal-galactosidase A (GalA), a key enzyme in the glycosphingolipid degradation pathway. FD is a complex disease with a poor genotype–phenotype correlation. In the early stages, FD could involve the peripheral nervous system (acroparesthesias and dysautonomia) and the ski (angiokeratoma), but later kidney, heart or central nervous system impairment may significantly decrease life expectancy. The advent of omics technologies offers the possibility of a global, integrated and systemic approach well-suited for the exploration of this complex disease. In this narrative review, we will focus on the main metabolomic studies, which have underscored the importance of detecting biomarkers for a diagnostic and prognostic purpose in FD. These investigations are potentially useful to explain the wide clinical, biochemical and molecular heterogeneity found in FD patients. Moreover, the quantitative mass spectrometry methods developed to evaluate concentrations of these biomarkers in urine and plasma will be described. Finally, the complex metabolic biomarker profile depicted in FD patients will be reported, which varies according to gender, types of mutations, and therapeutic treatment. MDPI 2022-07-28 /pmc/articles/PMC9415061/ /pubmed/36005574 http://dx.doi.org/10.3390/metabo12080703 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Rocchetti, Maria Teresa Spadaccino, Federica Catalano, Valeria Zaza, Gianluigi Stallone, Giovanni Fiocco, Daniela Netti, Giuseppe Stefano Ranieri, Elena Metabolic Fingerprinting of Fabry Disease: Diagnostic and Prognostic Aspects |
title | Metabolic Fingerprinting of Fabry Disease: Diagnostic and Prognostic Aspects |
title_full | Metabolic Fingerprinting of Fabry Disease: Diagnostic and Prognostic Aspects |
title_fullStr | Metabolic Fingerprinting of Fabry Disease: Diagnostic and Prognostic Aspects |
title_full_unstemmed | Metabolic Fingerprinting of Fabry Disease: Diagnostic and Prognostic Aspects |
title_short | Metabolic Fingerprinting of Fabry Disease: Diagnostic and Prognostic Aspects |
title_sort | metabolic fingerprinting of fabry disease: diagnostic and prognostic aspects |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415061/ https://www.ncbi.nlm.nih.gov/pubmed/36005574 http://dx.doi.org/10.3390/metabo12080703 |
work_keys_str_mv | AT rocchettimariateresa metabolicfingerprintingoffabrydiseasediagnosticandprognosticaspects AT spadaccinofederica metabolicfingerprintingoffabrydiseasediagnosticandprognosticaspects AT catalanovaleria metabolicfingerprintingoffabrydiseasediagnosticandprognosticaspects AT zazagianluigi metabolicfingerprintingoffabrydiseasediagnosticandprognosticaspects AT stallonegiovanni metabolicfingerprintingoffabrydiseasediagnosticandprognosticaspects AT fioccodaniela metabolicfingerprintingoffabrydiseasediagnosticandprognosticaspects AT nettigiuseppestefano metabolicfingerprintingoffabrydiseasediagnosticandprognosticaspects AT ranierielena metabolicfingerprintingoffabrydiseasediagnosticandprognosticaspects |